Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 12 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-3.32 Insider Own18.24% Shs Outstand82.15M Perf Week-4.00%
Market Cap177.44M Forward P/E- EPS next Y-1.88 Insider Trans71.56% Shs Float67.17M Perf Month-4.00%
Income-142.66M PEG- EPS next Q-0.44 Inst Own43.06% Short Float11.44% Perf Quarter-28.95%
Sales0.00M P/S- EPS this Y43.84% Inst Trans7.15% Short Ratio5.20 Perf Half Y44.00%
Book/sh3.93 P/B0.55 EPS next Y-0.99% ROA-53.03% Short Interest7.69M Perf Year-59.01%
Cash/sh1.94 P/C1.11 EPS next 5Y29.10% ROE-61.69% 52W Range1.10 - 7.50 Perf YTD14.29%
Dividend Est.- P/FCF- EPS past 5Y19.75% ROI-75.93% 52W High-71.20% Beta1.86
Dividend TTM- Quick Ratio8.41 Sales past 5Y342.10% Gross Margin- 52W Low96.36% ATR (14)0.16
Dividend Ex-Date- Current Ratio8.41 EPS Y/Y TTM-96.18% Oper. Margin0.00% RSI (14)44.09 Volatility5.24% 6.78%
Employees143 Debt/Eq0.12 Sales Y/Y TTM-100.00% Profit Margin- Recom1.50 Target Price9.20
Option/ShortYes / Yes LT Debt/Eq0.10 EPS Q/Q4.48% Payout- Rel Volume0.28 Prev Close2.24
Sales Surprise-100.00% EPS Surprise0.96% Sales Q/Q- EarningsMar 19 AMC Avg Volume1.48M Price2.16
SMA20-1.66% SMA50-13.77% SMA2004.72% Trades Volume416,385 Change-3.57%
Date Action Analyst Rating Change Price Target Change
Jun-27-23Downgrade JMP Securities Mkt Outperform → Mkt Perform
Jun-27-23Downgrade Guggenheim Buy → Neutral
Jun-01-23Downgrade JP Morgan Overweight → Neutral $20 → $6
Sep-21-22Initiated JP Morgan Overweight $23
Mar-31-22Initiated SMBC Nikko Outperform $28
Mar-08-22Initiated Truist Buy $30
Mar-04-22Initiated Jefferies Buy $27
May-18-21Initiated BTIG Research Buy $34
Apr-23-21Initiated H.C. Wainwright Buy $27
Apr-14-21Initiated Canaccord Genuity Buy $28
Apr-08-24 07:00AM
Apr-04-24 08:38AM
Apr-01-24 09:40AM
Mar-28-24 05:19PM
Mar-22-24 09:35AM
09:53PM Loading…
Mar-19-24 09:53PM
Mar-15-24 09:40AM
Mar-11-24 07:00AM
Feb-29-24 07:46PM
Feb-28-24 09:40AM
Feb-12-24 09:40AM
Feb-05-24 04:01PM
Jan-31-24 04:39PM
Jan-30-24 12:51PM
04:01PM Loading…
Jan-25-24 04:01PM
Jan-22-24 11:43PM
Jan-04-24 07:00AM
Jan-03-24 04:01PM
Dec-29-23 04:50PM
Dec-10-23 12:00PM
Nov-08-23 04:10PM
Nov-07-23 07:00AM
Nov-02-23 09:00AM
Oct-31-23 06:25PM
Oct-04-23 12:00PM
Sep-29-23 05:24PM
Sep-27-23 09:00AM
04:35PM Loading…
Aug-31-23 04:35PM
Aug-12-23 08:16AM
Aug-09-23 04:15PM
Aug-02-23 04:00PM
Jul-31-23 04:50PM
Jul-11-23 08:30AM
Jun-30-23 04:51PM
Jun-26-23 04:00PM
Jun-01-23 07:00AM
May-31-23 04:53PM
May-18-23 06:00AM
May-09-23 04:30PM
Apr-28-23 05:13PM
Apr-26-23 08:01PM
Apr-17-23 06:58AM
Apr-13-23 07:00AM
Apr-04-23 02:47PM
Mar-31-23 04:31PM
Mar-15-23 04:01PM
Mar-09-23 07:00AM
Mar-05-23 07:09AM
Feb-28-23 05:31PM
Feb-01-23 07:00AM
Jan-31-23 08:40PM
Dec-30-22 04:43PM
Dec-20-22 08:23AM
Dec-10-22 10:00AM
Dec-02-22 07:00AM
Nov-30-22 08:08PM
Nov-29-22 07:00AM
Nov-11-22 05:24AM
Nov-08-22 04:10PM
Nov-07-22 08:00AM
Nov-03-22 09:00AM
Nov-01-22 07:00AM
Oct-31-22 06:58PM
Oct-23-22 08:39AM
Oct-05-22 08:00AM
Sep-30-22 06:59PM
Sep-26-22 06:26AM
Sep-07-22 04:10PM
Aug-31-22 05:30PM
Aug-16-22 06:16AM
Aug-10-22 07:00AM
Aug-01-22 04:10PM
Jul-29-22 06:05PM
Jul-01-22 04:10PM
Jun-21-22 04:10PM
Jun-06-22 07:00AM
Jun-03-22 04:10PM
May-26-22 05:00PM
May-18-22 04:00PM
May-15-22 08:21AM
May-12-22 04:10PM
May-05-22 07:00AM
May-04-22 04:10PM
Apr-27-22 10:00AM
Apr-19-22 07:00AM
Apr-07-22 04:10PM
Apr-01-22 04:10PM
Mar-22-22 12:47PM
Mar-15-22 04:00PM
Mar-04-22 04:00PM
Feb-02-22 07:00AM
Dec-10-21 04:01PM
Adicet Bio, Inc. is a clinical stage biotechnology company, which engages in discovering and developing allogeneic gamma delta T cell therapies for cancer. It also focuses on developing a pipeline of "off-the-shelf" gamma delta T cells. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ORBIMED ADVISORS LLCDirectorJan 25 '24Buy2.403,125,0007,500,0007,526,359Jan 26 07:14 PM
GORDON CARL LDirectorJan 25 '24Buy2.403,125,0007,500,0007,526,359Jan 26 07:13 PM
Schor ChenPresident & CEOOct 02 '23Buy1.335,5007,34043,469Oct 02 08:16 PM
Schor ChenPresident & CEOSep 29 '23Sale1.365,5007,481176,969Oct 02 08:16 PM
Schor ChenPresident & CEOSep 28 '23Buy1.425,5007,810182,469Oct 02 08:16 PM
Schor ChenPresident & CEOSep 28 '23Sale1.425,5007,81037,969Oct 02 08:16 PM
DUBIN STEVEDirectorJun 30 '23Buy2.405,00012,00010,900Jun 30 04:08 PM
ORBIMED ADVISORS LLCDirectorJun 27 '23Buy2.09875,0001,828,7505,685,259Jun 29 04:46 PM
GORDON CARL LDirectorJun 27 '23Buy2.09875,0001,828,7505,685,259Jun 29 04:51 PM